TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of PN for at least 3 months before screening.~* Inadequate response or intolerant to ongoing or prior PN therapy.~* ≥ 20 pruriginous lesions on ≥ 2 different body regions at screening and Day 1.~* Willingness to avoid pregnancy or fathering children~* Further inclusion criteria apply.~Exclusion Criteria:~* Have chronic pruritus due to a condition other than PN; have neuropathic and psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis.~* Current use of a medication known to cause pruritus.~* Women who are pregnant (or who are considering pregnancy) or lactating.~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.~* Laboratory values outside of the protocol-defined ranges.~* Further exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INCB054707 Dose A (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
- INCB054707 Dose B (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
- INCB054707 Dose C (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
- Placebo followed by INCB054707 Dose B or C (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with liver cirrhosis with the 1 year risk of HCC of 5% or higher meeting all of following criteria;~1. The evidence of cirrhosis of any etiology within 12 months prior to screening Definition of cirrhosis by any of following methods~   * 1) Histologically by liver biopsy;~  * 2) Non-histologically by evidence of portal hypertension in the presence of chronic liver disease;~     * Evidence of portal hypertension, including any of followings;~       1. The identification of splenomegaly on USG, CT, or MRI examinations with typical features of cirrhosis~      2. The identification of esophageal or gastric varices on endoscopic examination~2. High Risk Index (\>=2.33); Risk Index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus \[HCV\] or hepatitis B surface antigen \[HBsAg\] is positive).~3. Older than 20 years of age~4. Absence of previous or current history of HCC~5. Absence of HCC should be identified by liver USG, dynamic CT, or contrast-enhanced MRI within 6 months prior to screening~6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2~7. Patient is able to comply with scheduled visits, evaluation plans, and other study procedures.~8. Patient is willing to provide written informed consent~Exclusion Criteria:~Presence of any of following criteria;~1. Active or suspected cancer other than HCC, or a history of malignancy where the risk of recurrence is \>20% within 2 years~2. Child-Pugh score \>9~3. Significant medical comorbidities in which survival is predicted to be less than 3 years~4. Estimated glomerular filtration rate (GFR) \< 30 mL/min/1.73m2~5. Precautions for MRI (cardiac pacemaker, ferromagnetic implants, etc.)~6. Severe claustrophobia that may interfere with protocol compliance.~7. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completing the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCC high-risk group (Type: None): Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (\>=2.33)~Risk Index = 1.65 (if the prothrombin activity is \<=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is \<=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus \[HCV\] or hepatitis B surface antigen \[HBsAg\] is positive).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All patients must be able to give informed consent.~The definition of severe asthma will be on the basis of:~1. Treatment: High dose of ICS ± OCS ≥ 1000mcg FP daily or equivalent plus one other controller medication.~2. Disease Control: Uncontrolled (GINA guidelines), three or more of the following present in any week in the preceding 4 weeks:~   1. Daytime symptoms more than twice per week~  2. Any limitation of activities~  3. Nocturnal symptoms once or more per week~  4. Need for reliever treatment more than twice per week~  5. Prebronchodilator FEV1 \<80% predicted or personal best AND/OR Frequent severe exacerbations (≥2 per year requiring high dose OCS or doubling of maintenance dose for at least three days or requiring hospitalisation).~3. Asthma Diagnosis:~Improvement in FEV1 ≥ 12% or 200ml predicted after inhalation of 400mcg salbutamol OR Diurnal variation in PEF: amplitude % mean of twice daily PEF \> 8% OR Decrease in FEV1 ≥ 12% and \>200ml within 4 weeks after tapering treatment with one or more of the following drugs: ICS, OCS, LABA, SABA PLUS A history of wheeze occurring spontaneously or on exertion.~Exclusion Criteria:~1. Patients with a FEV1 \< 1L~2. Any other active lung condition~3. Subjects unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Astma patients (Type: EXPERIMENTAL): Participant undergoes a bronchoscopy to isolate epithelial cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical diagnosis as confirmed by the M.I.N.I. meeting criteria from the Diagnostic and Statistical Manual of Mental disorders, 4th Edition (DSM-IV) for any of the following:296.2x MDD, Single Episode296.3x MDD, Recurrent Episode~* Current episode of depression present, at least 42 days prior to enrolment but not more than 18 months~* MADRS-Score ≥ 25 at enrolment and randomisation~Exclusion Criteria:~* Patients with a DSM-IV Axis I disorder other than MDD within 6 months of randomisation~* Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status~* Patients who, in the investigator's judgment pose a current serious suicidal or homicidal risk, or have made a suicide attempt within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Add-on Quetiapine XR+SSRI/Venlafaxine (Type: ACTIVE_COMPARATOR): Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline.
- Add-on Lithium+SSRI/Venlafaxine (Type: ACTIVE_COMPARATOR): Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline.
- Monotherapy Quetiapine XR (Type: ACTIVE_COMPARATOR): Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female aged 18 to 75 years, inclusive.~* Patient has moderately to severely active UC with a modified Mayo score of 5 to 9 points with endoscopic subscore of ≥ 2 points~Exclusion Criteria:~* Patient who has previously received 2 or more biologic agents and/or JAK inhibitors~* Patient who has previously received either a TNFα inhibitor or biologic agent within 5 half-lives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 SC (Type: EXPERIMENTAL): None
- Placebo SC (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* Stage 3-5 CKD~* hs-CRP \> 2.0 mg/L~* Comply with contraception~Exclusion Criteria:~* Low neutrophil count~* Low platelet count~* Spot urine protein to creatinine ration \> 4000 mg/g~* ALT/AST \>2.5x ULN~* TSAT \< 10%~* Positive TB test~* Evidence of HIV, hepatitis B~* Blind or illiterate~* Expected to require blood transfusion~* Thromboembolic event within 12-weeks~* Evidence of active infection~* Peptic ulcer disease, diverticulitis, inflammatory bowel disease~* Uncontrolled hypertension~* Planned coronary revascularization~* Major cardiac surgery, CHF~* Active malignancy, bone marrow or organ transplant~* Allergy to study drug~* Treatment with investigational drug, treatment with HIF stabilizer or ESA~* Use of immunosuppressive drugs, systemic antibiotics~* Breastfeeding, any other significant medical history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo
- Ziltivekimab 7.5 mg (Type: EXPERIMENTAL): None
- Ziltivekimab 15 mg (Type: EXPERIMENTAL): None
- Ziltivekimab 30 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from parent or legal guardian of the infant or child~* Age \>= 9 months and \<4 years at recruitment~* Eligible to receive a single dose of Hib vaccine as per the UK schedule~* Receipt of three doses of Hib vaccine in infancy~Exclusion Criteria:~* History of Hib infection~* History of severe local reaction that can be confidently related to a prior Hib immunisation~* Deferral of vaccination if acute illness and/or temperature \>38C on day of vaccination

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 4 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting within 6 h after onset of chest pain lasting for more than 30 min and with significant ST-segment elevation on ECG.~Exclusion Criteria:~* BP \>180/110~* Known bleeding disorder~* Cardiogenic shock~* CPR\>10 min~* Ongoing anticoagulant therapy~* Renal insufficiency~* Weight \>120 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- thrombolysis (Type: ACTIVE_COMPARATOR): None
- invasive (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Resistance Information Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants greater than or equal to (≥) 1 year of age with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness (during Years 1 to 5)~* Participants less than or equal to (≤) 12 years of age with a positive diagnostic test of influenza and displaying symptoms suggestive of influenza-like illness and who are being or, according to local standard of care, will be treated with an influenza antiviral (during Years 6 and 7)~Exclusion Criteria:~* Allergy to any potential influenza therapy~* Living in the same household or residential/care home as another study participant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants Infected with Influenza (Type: None): Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject male or female with age over 18 years old~2. Diagnosis of non-segmental (symmetrical) vitiligo~3. Presence of at least one vitiligo target-plaque on the face, with:~   Area greater than 3cm² Local Vitiligo Area Severity Index (VASI) score ≥ 50% Stable (no change in pigmentation or size over the last 3 months) Recent onset (less than 2 years duration)~4. Subject affiliated to the French social security system~Exclusion Criteria:~1. Progressive vitiligo over the last 3 months~2. Spontaneous ongoing repigmentation (documented in the last 3 months)~3. Previous topical Tacrolimus treatment in the last 3 months~4. Previous topical or systemic treatment in the last month:~   Topical or oral corticosteroid Topical vitamin D Phototherapy or laser Other topical treatment specific to vitiligo Other immunosuppressant or immunomodulator~5. Underlying dermatological disease (i.e.: history of atopic dermatitis, eczema, psoriasis), which, according to the investigator, could interfere with the study assessments~6. Known sensitivity to study drug or macrolides~7. Past history of skin cancer or lymphoma~8. Congenital or acquired immunodeficiency~9. Pregnant or breastfeeding women~10. Women without contraception~11. Absence of signed informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus group (Type: EXPERIMENTAL): Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
- Control group (Type: PLACEBO_COMPARATOR): In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) \>= 30 and \< 50~* BMI \>= 27 and \< 50 if patient has controlled hypertension or abnormal blood lipids~* Stable weight~* Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test)~Exclusion Criteria:~* Known contraindication, or hypersensitivity to topiramate~* A diagnosis of diabetes (except those diagnosed during the enrollment if no medications are needed)~* History or evidence of clinically significant liver, disease, cardiovascular disease, uncontrolled hypertension or high thyroid levels~* History of obesity with known cause~* History of weight loss surgery or liposuction~* History of malignancy within last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Male of female gender~* Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent~* In case of women, unwillingness to remain pregnant during the study period achieved either by their partner using condom or by themselves using oral contraceptives.~* Confirmed infection by SARS-CoV-2 virus~* Infection of the upper respiratory tract or of the lower respiratory tract~Exclusion Criteria:~* Age below 18 years~* Denial of written informed consent~* Intake of any macrolide for the current episode of infection under study~* Intake of hydroxychloroquine or chloroquine phosphate.~* Presence of severe respiratory failure~* Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 15 days~* Neutropenia defined as an absolute neutrophil count below 1,000/mm3~* Presence of any contraindications for the study drugs as stated in local label information~* QTc interval at rest electrocardiogram ≥500 msec or history of known congenital long QT syndrome~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clarithromycin arm (Type: EXPERIMENTAL): Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete